Full-Time
Principal/Sr Scientist
Confirmed live in the last 24 hours
ProKidney
51-200 employees
Develops cell therapy for chronic kidney disease
Senior
Morrisville, NC, USA
Position requires on-site presence in Morrisville, North Carolina.
- Master’s degree with 3+ years of relevant experience or PhD in cell biology/physiology or closely related field Evidence of peer-reviewed published experience preferred
- 4+ years of cell-based research experience
- Use aseptic cell culture techniques to cultivate and expand human or other mammalian cells
- Prepare 3-dimensional cellular constructs including organoids and assembloids
- Conduct cell function assays – cargo uptake including proteins and ions; ion exchange; tubule formation assay; organoid size and cell count
- Support mRNA synthesis efforts from cell cultures and organoids
- Fluorescent immunoantibody staining of cells and/or organoids
- Image capture and analysis
- Perform tissue culture techniques to establish *ex vivo* kidney model systems from human samples (e.g. organoids in matrigel)
- Participate in the development of sophisticated *in vitro* model systems such as organoids and combination culture (assembloids)
- Utilize common molecular and cell biology skills including immunohistochemistry, immunofluorescence, single cell sequencing, etc., to characterize organoids
- Record all data and summarize in an organized fashion
- Work with the lab head and other members to design, develop, and execute experiments
ProKidney focuses on treating Chronic Kidney Disease (CKD) through a novel cell therapy called rilparencel. This therapy aims to preserve kidney function in patients with advanced CKD, potentially delaying or eliminating the need for dialysis, which many patients currently rely on. ProKidney is in the late stages of clinical trials, and early results indicate that rilparencel may effectively maintain kidney function. Unlike other treatments, ProKidney specifically targets CKD, a condition affecting over 35 million adults in the U.S., and aims to fill a significant gap in available therapies. The company's goal is to provide a groundbreaking treatment that improves the quality of life for CKD patients and reduces their reliance on dialysis.
Company Stage
IPO
Total Funding
$559.3M
Headquarters
Winston-Salem, North Carolina
Founded
N/A
6 month growth
↑ 14%1 year growth
↑ 50%2 year growth
↑ 87%
Simplify's Take
What believers are saying
- Successful $140 million public and direct offering boosts financial stability and supports ongoing R&D efforts.
- The potential approval and commercialization of rilparencel could revolutionize CKD treatment and significantly improve patient quality of life.
- Expansion plans, including a new facility in Greensboro, promise job creation and economic growth.
What critics are saying
- The biotech sector's inherent volatility, as evidenced by ProKidney's significant stock price fluctuations, could impact financial stability.
- Dependence on the successful approval and commercialization of rilparencel means any regulatory setbacks could severely affect the company's prospects.
What makes ProKidney unique
- ProKidney is pioneering a novel cell therapy, rilparencel, specifically targeting CKD, unlike many competitors who focus on broader therapeutic areas.
- Their focus on delaying or eliminating the need for dialysis offers a unique value proposition in the CKD treatment landscape.
- ProKidney's late-stage clinical trials and promising early data position it as a frontrunner in CKD cell therapy innovation.
Help us improve and share your feedback! Did you find this helpful?